Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

303.29

Mkt cap

6.3B

Volume

934K

High

303.29

P/E Ratio

-11.53

52-wk high

368.29

Low

272.72

Div yield

N/A

52-wk low

166.00

Madrigal Pharmaceuticals has received accelerated FDA approval for Rezdiffra (resmetirom) for treating noncirrhotic NASH with moderate to advanced liver fibrosis. The approval is conditional on further verification from ongoing trials. Rezdiffra, which does not require a liver biopsy for diagnosis, has dosages based on body weight and will be available in the U.S. in April through a specialty pharmacy network.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:22 pm

The FDA has approved Rezdiffra for use alongside diet and exercise for the treatment of adults with NASH (Nonalcoholic Steatohepatitis) with moderate to advanced liver fibrosis. This marks a significant advancement in the treatment options available for patients suffering from this condition.

Portfolio Pulse from Happy Mohamed

March 14, 2024 | 7:45 pm

The FDA has approved Madrigal Pharmaceuticals' Rezdiffra, according to Reuters citing the company's website.

Portfolio Pulse from Happy Mohamed

March 14, 2024 | 7:44 pm

Trading for MDGL was halted at 3:29:48 p.m. ET due to pending news. This action indicates that significant news is expected to be released, which could materially impact the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 7:29 pm

Piper Sandler analyst Yasmeen Rahimi has reiterated an Overweight rating on Madrigal Pharmaceuticals (MDGL) and maintained a price target of $336. This reaffirmation highlights the analyst's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 2:57 pm

The American Association for the Study of Liver Diseases (AASLD) celebrates the FDA's approval of Madrigal Pharmaceuticals' resmetirom for MASH treatment. Resmetirom, a liver-directed therapy, is the first FDA-approved treatment specifically for Metabolic dysfunction-Associated Steatohepatitis (MASH), addressing a significant unmet need in liver disease management. This approval is seen as a major advancement in hepatology, offering new hope for patients with MASH, a condition characterized by liver inflammation and fibrosis due to fat accumulation.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 2:03 pm

Madrigal Pharmaceuticals' stock price increased following an upgrade in its price target from $275 to $405 by HC Wainwright & Co.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:08 pm

HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $275 to $405.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:23 am

Canaccord Genuity analyst Edward Nash maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $336 to $338.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 5:15 pm

Madrigal Pharmaceuticals' stock (MDGL) is trading higher following Citigroup's initiation of coverage with a Buy rating and a $382 price target.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 3:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.